share_log

Invitation to Mendus' Update on Vididencel Program as Online and On-site Events on June 27th, 2023

Invitation to Mendus' Update on Vididencel Program as Online and On-site Events on June 27th, 2023

邀請參加2023年6月27日門德斯關於Vididencel計劃的最新在線和現場活動
GlobeNewswire ·  2023/06/15 14:00

Mendus AB ("Mendus" publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence, will provide an update on its lead program vididencel on Tuesday, June 27, 2023. The update will take place in an online event and, separately, on-site at the company's headquarters in Stockholm, Sweden.

MENDUS AB(“MENDUS”publ;IMMU.ST)是一家專注於治療腫瘤復發的免疫療法的生物製藥公司,該公司將於2023年6月27日(星期二)提供其領先計劃vididencel的最新情況。更新將在一個在線活動中進行,並將在瑞典斯德哥爾莫耳的公司總部現場進行。

During the events, Mendus' leadership team will present the key elements of the development path for vididencel, including the clinical trial strategy and the recently announced alliance with Sweden-based biologics manufacturer NorthX Biologics.

在活動期間,Mendus的領導團隊將介紹Vididencel發展道路的關鍵要素,包括臨床試驗戰略以及最近宣佈的與瑞典生物製品製造商NorthX Biologics的聯盟。

Online event

線上活動

This meeting will be held as an online event, for which dial-in details will be provided via the corporate website in due time.

本次會議將以在線活動的形式舉行,撥入細節將在適當的時候通過公司網站提供。

Date: Tuesday, June 27, 2023

日期:2023年6月27日(星期二)

Time: 10.00 - 11.00 CEST, registration via the registration link to be provided via

時間:10:00-11:00 CEST,通過註冊鏈接註冊將通過以下方式提供

A replay of the webcast will be available via the corporate website following the live event.

直播活動結束後,將通過公司網站重播網路直播。

On-site event at Mendus' premises in Stockholm, Sweden

門杜斯的現場活動瑞典斯德哥爾莫耳的辦公場所

The event will start with a presentation by the Management Team followed by a Q&A session. Questions for the management team can be sent to ir@mendus.com prior to the event or addressed after the presentation by the Management Team.

活動將首先由管理團隊進行陳述,然後是問答環節。向管理團隊提出的問題可在活動前發送至ir@mendus.com,或在介紹後由管理團隊解答。

This meeting will be held as an on-site event, which will be open to in-person attendance only.

本次會議將作為現場活動舉行,僅限面對面參加。

Date: Tuesday, June 27, 2023

日期:2023年6月27日(星期二)

Venue: Tändstickspalatset, Västra Trädgårdsgatan 15, Stockholm

地點:Tändtickspalatset,Västra TräDgårdsgatan 15,斯德哥爾莫耳

Time: 18.00 - 20.00 CEST, registration in-person attendance starting at 17.30

時間:中歐標準時間18:00-20:00,17:30開始親自報名

Since capacity is limited, please register your interest to participate in the event by email to ir@mendus.com prior to June 21, 2023.

由於容量有限,請在2023年6月21日之前通過電子郵件將您的興趣發送到ir@mendus.com。

ABOUT VIDIDENCEL

視頻

Vididencel is a whole cell-based vaccine designed to improve immunity against residual cancer cells. Vididencel is being developed as a cancer maintenance therapy, aimed at prevention or delay of tumor recurrence, the leading cause of cancer-related deaths. Vididencel is currently studied in a Phase 2 monotherapy trial (ADVANCE II) in acute myeloid leukemia (AML), a blood-borne tumor which leads to recurrence in the majority of patients within the first year after high-intensity chemotherapy, due to residual disease. In the most recent read-out of the ADVANCE II trial of December 2022, the majority of patients (12/20) were alive and disease-free after the initial 70-week study period with follow up ranging from 16-47 months, despite having measurable residual disease at study entry. In a next study, vididencel will be combined with the currently approved drug for AML maintenance, oral azacitidine, as a step-up to pivotal-stage development. Mendus expects this new trial to start in 2023H2. An additional survival read-out for the ongoing ADVANCE II trial is expected 2023Q4.

Vididencel是一種基於全細胞的疫苗,旨在提高對殘留癌細胞的免疫力。Vididencel正在被開發為一種癌症維持療法,旨在預防或推遲腫瘤復發,腫瘤復發是癌症相關死亡的主要原因。Vididencel目前正在進行2期單一療法試驗(Advance II),用於治療急性髓細胞白血病(AML),這是一種血液傳播的腫瘤,由於殘留疾病,大多數患者在高強度化療後第一年內會復發。在2022年12月對Advance II試驗的最新讀出中,大多數患者(12/20)在最初的70周研究期後存活並無疾病,隨訪時間從16-47個月不等,儘管在研究開始時有可測量的殘留病。在下一項研究中,vididencel將與目前批准的治療急性髓細胞白血病的藥物口服氮胞替丁聯合使用,作為進入關鍵階段開發的一步。門杜斯預計這項新的試驗將於2023年下半年開始。正在進行的Advance II試驗的額外生存讀數預計將於2023年第四季度公佈。

ABOUT THE NORTHX BIOLOGICS ALLIANCE

NORTHX生物製品聯盟

On June 8, 2023, Mendus announced that it has entered into a manufacturing alliance with NorthX Biologics AB ("NorthX"). NorthX is a Contract Development and Manufacturing Organization (CDMO) and serves as the National Swedish Innovation Hub for the GMP manufacture of biologics used in vaccines, gene therapy and other advanced therapy medicinal products (ATMPs). Mendus and NorthX will co-establish cell therapy manufacturing capabilities in Sweden, which will be used for late-stage development and commercial manufacturing of vididencel.

2023年6月8日,門杜斯宣佈與NorthX Biologics AB(簡稱NorthX)達成製造聯盟。NorthX是一個合同開發和製造組織(CDMO),是瑞典國家創新中心,負責疫苗、基因治療和其他先進治療藥物產品(ATMP)中生物製劑的GMP製造。Mendus和NorthX將在瑞典共同建立細胞治療製造能力,用於Vididencel的後期開發和商業製造。

ABOUT MENDUS AB (PUBL)

關於Mendus AB(Publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST.

MENTUS致力於通過解決腫瘤復發和改善癌症患者的生存結果來改變癌症治療的進程,同時保持生活品質。我們正在利用我們在同種異體樹突狀細胞生物學方面的無與倫比的專業知識,開發一種先進的新型、現成、基於細胞的免疫療法,將臨床療效與良性安全性結合在一起。門杜斯總部位於瑞典和荷蘭,在斯德哥爾莫耳納斯達克上市,股票代碼為IMMU.ST。

FOR MORE INFORMATION, PLEASE CONTACT:

如需更多資訊,請聯繫:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com

埃裡克·曼廷
首席執行官
電郵:郵箱:ir@mendus.com

INVESTOR RELATIONS
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com

投資者關係
科裡·戴維斯
生活科學顧問有限責任公司
電話:+1212-915-2577
電郵:郵箱:cdavis@lifescivisors.com

MEDIA RELATIONS

媒體關係

Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu

馬利奧·布爾庫爾傑
價位通信
電話:+4916093529951
電郵:郵箱:mbrkulj@valencycoms.eu

Attachment

依附

  • 230615_Mendus_Invitation_June_IR_Webcast_ENG
  • 230615_菜單邀請_六月_IR_網路廣播_英文

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論